Therapeutics and Clinical Risk Management, 2022 Zeyu Xie, Jinjian Li, Sensen Yang, Weishang Deng, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Li J, Yang S, Deng W, Chen J
doaj
GLP-1 and Its Role in Glycogen Production: A Narrative Review
BiomedicinesGlucagon-like peptide-1 (GLP-1) has emerged as a pivotal regulator in the management of glucose homeostasis, glycogen metabolism, and energy balance, positioning it as a critical therapeutic target for addressing obesity, metabolic syndrome, and type 2 ...
Joseph Lotosky +8 more
doaj +1 more source
Protective potential of glucagon like peptide 2 (GLP-2) against the neurodegeneration [PDF]
, 2019 Neurodegeneration consists in loss of neuron specific types, pattern and distribution, leading to progressive dysfunctions of the central nervous system.
Amato, Antonella, Mulè, Flavia
core +1 more source
A neuronal relay mediates a nutrient responsive gut/fat body axis regulating energy homeostasis in adult Drosophila [PDF]
, 2019 The control of systemic metabolic homeostasis involves complex inter-tissue programs that coordinate energy production, storage, and consumption, to maintain organismal fitness upon environmental challenges.
Bauer, Christin +8 more
core +1 more source
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels [PDF]
, 2019 学位記番号 ...
Suga, Takayoshi +2 more
core
Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]
, 2018 Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V. +9 more
core +1 more source
Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]
, 2017 Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B. +7 more
core +2 more sources
Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Diabetes & MetabolismGlucagon-like peptide-1 (GLP-1) is an incretin hormone, secreted from gut endocrine cells, which acts to potentiate nutrient-induced insulin secretion. Activation of its receptor, GLP-1R, decreases glucagon secretion and gastric emptying, thereby decreasing blood glucose and body weight. It is largely through these mechanisms that Glucagon-like peptide-
Chen J, Cooper ME, Coughlan MT
openaire +2 more sources
Physiology and pharmacology of glucagon-like peptide-1 receptor
Фармация и фармакология (Пятигорск)Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks.
D. V. Kurkin +15 more
doaj +1 more source
Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. [PDF]
, 2016 Glucagon is one of the main regulators of blood glucose levels and dysfunctional stimulus secretion coupling in pancreatic A-cells is believed to be an important factor during development of diabetes.
Ahlstedt, I. +3 more
core +1 more source